1. Home
  2. VRDN vs VVX Comparison

VRDN vs VVX Comparison

Compare VRDN & VVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRDN
  • VVX
  • Stock Information
  • Founded
  • VRDN 2006
  • VVX 2014
  • Country
  • VRDN United States
  • VVX United States
  • Employees
  • VRDN N/A
  • VVX N/A
  • Industry
  • VRDN Medical Specialities
  • VVX Diversified Commercial Services
  • Sector
  • VRDN Health Care
  • VVX Consumer Discretionary
  • Exchange
  • VRDN Nasdaq
  • VVX Nasdaq
  • Market Cap
  • VRDN 1.6B
  • VVX 1.5B
  • IPO Year
  • VRDN N/A
  • VVX 2014
  • Fundamental
  • Price
  • VRDN $13.48
  • VVX $49.05
  • Analyst Decision
  • VRDN Buy
  • VVX Buy
  • Analyst Count
  • VRDN 12
  • VVX 8
  • Target Price
  • VRDN $36.44
  • VVX $65.38
  • AVG Volume (30 Days)
  • VRDN 766.3K
  • VVX 312.1K
  • Earning Date
  • VRDN 05-07-2025
  • VVX 05-06-2025
  • Dividend Yield
  • VRDN N/A
  • VVX N/A
  • EPS Growth
  • VRDN N/A
  • VVX N/A
  • EPS
  • VRDN N/A
  • VVX 1.08
  • Revenue
  • VRDN $302,000.00
  • VVX $4,322,155,000.00
  • Revenue This Year
  • VRDN N/A
  • VVX $4.55
  • Revenue Next Year
  • VRDN $17,629.40
  • VVX $4.91
  • P/E Ratio
  • VRDN N/A
  • VVX $45.51
  • Revenue Growth
  • VRDN N/A
  • VVX 9.06
  • 52 Week Low
  • VRDN $11.40
  • VVX $41.08
  • 52 Week High
  • VRDN $27.20
  • VVX $69.75
  • Technical
  • Relative Strength Index (RSI)
  • VRDN 32.50
  • VVX 49.29
  • Support Level
  • VRDN $14.03
  • VVX $49.12
  • Resistance Level
  • VRDN $15.91
  • VVX $52.58
  • Average True Range (ATR)
  • VRDN 0.67
  • VVX 1.90
  • MACD
  • VRDN -0.10
  • VVX 0.04
  • Stochastic Oscillator
  • VRDN 6.51
  • VVX 32.89

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

About VVX V2X Inc.

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

Share on Social Networks: